Effects of valsartan and nebivolol on blood pressure, QT dispersion and left ventricular hypertrophy in hypertensive patients

Year 2010, Volume: 37 Issue: 2, 81 - 88, 01.06.2010

Luminita Lăţea Ştefania L. Negrea Sorana D. Bolboacă

Abstract

Objectives: The aim of this study was to analyze the an­tihypertensive effect of Valsartan and Nebivolol and their effects on QT dispersion and left ventricular hypertrophy (LVH) in the treatment of naive hypertensive patients. Methods: A prospective study with a six-month follow-up was conducted on hypertensive patients with LVH and mild/ moderate essential hypertension. The patients were randomly assigned to Valsartan (80 to 160 mg/day) or Nebivolol (5 to 10 mg/day) groups. The study group con­sisted of 108 patients, 55 in the Valsartan group and 53 in the Nebivolol group. Results: The range of mean systolic blood pressure (SBP) varied from 152±17 (baseline) to 132±17 mmHg (follow-up) in the Valsartan group (p

Keywords

Hypertension, electrocardiography, left ven­tricular hypertrophy, QT interval, QTc, echocardiography.

Hipertansif hastalarda valsartan ve nebivololun, kan basıncı, QT dağılımı ve sol ventrikül hipertrofisi üzerine etkileri

Abstract

Amaç: Bu çalışmanın amacı valsartan ve nebivololun an­tihipertansif etkilerini ve bu ilaçların hipertansif hastaların tedavisinde QT dağılımı ve sol ventrikül hipertrofisi üzeri­ne etkilerini analiz etmektir. Yöntemler: Sol ventrikül hipertrofisi (SVH) bulunan ha­fif/orta hipertansiyonlu hastalarda 6 ay süreli takip içe­ren prospektif bir çalışma düzenlendi. Hastalar rastgele olarak Valsartan (80-160 mg/gün) veya Nebivolol (5-10 mg/gün) gruplarına alındı. Çalışma grubu 55\'i Valsartan grubu, 53\'ü Nebivolol grubunda olmak üzere toplam 108 hastadan oluşturuldu. Bulgular: Valsartan grubunda ortalama sistolik kan ba­sıncı (SKB) 152±17 mmHg (bazal)\'den 132±17 mmHg (takip)\'e değişti (p

Keywords

Hipertansiyon, elektrokardiyografi, sol ventrikül hipertrofisi, QT aralığı, ekokardiyografi

References

• Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992;13:82-8.
• Savage DD, Garrison RJ, Kannel WB, et al. The spectrum of left ventricular hypertrophy in a general population sample: the Framingham study. Circulation 1987;75:126-33.
• Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long QT syndrome. N Engl J Med 2003;348:1866- 74.
• Bazett HC. An analysis of the time-relations of electrocardio- grams. Heart 1920;7:353-70.
• Oikarinen L, Nieminen MS, Viitasalo M, et al. LIFE Study Investigators. QRS duration and QT interval predict mor- tality in hypertensive patients with left ventricular hyper- trophy. Hypertension 2004;43:1029-34.
• Rasmussen KG, Hooten WM, Dodd ML, Ryan DA.QTc dis- persion on the baseline ECG predicts arrhythmias during electroconvulsive therapy. Acta Cardiol 2007;62:345-7.
• Yildirir A, Batur MK, Oto A. Hypertension and arrhythmia: blood pressure control and beyond. Europace 2002;4:175- 82.
• Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essen- tial hypertension. Am J Med 2003;115 41-6.
• Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: Focus on left ven- tricular hypertrophy regression and atrial fibrillation pre- vention. Vasc Health Risk Manag 2008;4: 67-73.
• Lim PO, Nys M, Naas AA, et al. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999;33:713-8.
• Sampson UK, Pfeffer MA, McMurray JJV, et al. Predic- tors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. Eur Heart J 2007;28: 685-91.
• Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res 1998;38:419-31.
• Sule SS, Frishman W. Nebivolol: new therapy update. Car- diol Rev 2006;14:259-64.
• Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-genera- tion ß-adrenergic blocker. Ann Pharmacother 2006;40:1353- 60.
• Pessina AC. Metabolic effects and safety profile of nebiv- olol. J Cardiovasc Pharmacol 2001;38:S33-S35.
• Toda N. Vasodilating ß-adrenoceptor blockers as cardiovas- cular therapeutics. Pharmacol Ther 2003;100:215-34.
• Ambrosioni E, Borghi C. Tolerability of nebivolol in head- tohead clinical trials versus other cardioselective β-blockers in the treatment of hypertension: a meta-analysis. High Blood Press Cardiovasc Prev 2005;12:27-35.
• European Society of Hypertension - European Society if Cardiology Guidelines Committee. 2007 Ecuropean So- ciety of Hypertension - European Society of Cardiology guidelines for the Management of Arterial Hypertension. Eur Heart J 2007;28:1462-536.
• Devereux RB, Reichek N. Echocardiographic determina- tion of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55: 613-8.
• Schiller NB, Shah PM, Crawford M, et al.Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocar- diogr 1989;2:358-67.
• Devereux RB, Reichek N. Echocardiographic determina- tion of left ventricular mass in man: Anatomic validation of the method. Circulation 1977:55:613-8.
• Drugan T, Bolboacă S, Jäntschi L, Achimaş Cadariu A. Bi- nomial Distribution Sample Confidence Intervals Estima- tion 1. Sampling and Medical Key Parameters Calculation. Leonardo El J Pract Technol 2003;3:47-74.
• Bolboacă S, Jäntschi L, Achimaş Cadariu A. Binomial Dis- tribution Sample Confidence Intervals Estimation 2. Pro- portion-like Medical Key Parameters. Leonardo El J Pract Technol 2003;3:75-110.
• Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and anti- hypertensive effect with nebivolol and losartan. Am J Hy- pertens 2005;18:1060-6.
• Balanescu S. Galinier M., Fourcade J, et al. Correlation be- tween QT interval dispersion and ventricular arrhythmia in hypertension. Arch Mal Coeur Vaiss 1996;89:987-90.
• De Bruyne MC, Hoes AW, Kors JA, et al. QTc dispersion predicts cardiac mortality in the elderly: The Rotterdam Study. Circulation 1998;97:467-72.
• Miyajima K, Minatoguchi S, Ito Y, et al. Reduction of QTc dispersion by the Angiotensin II receptor Blocker Valsartan May Be Related to its anti-oxidative stress effect in patients with essential hypertension. Hypertens Res 2007;30:307- 13.
• Brooksby P, Robinson PJ, Segal R, et al. Effects of losar- tan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. Lancet 1999;354: 395-6.
• Davila DF, Donis JH, Odreman R, et al. Patterns of left venmtricular hypertrophy in essential hypertension: should echocardiography guide the pharmacological treatment? Int J Cardiol 2008; 124: 134-8.
• Galinier M., Balanescu S., Fourcade J, et al. Prognostic value of ventricular arrhythmias in systemic hypertension. J Hypertens 1997;15:1779-83.
• Gavras I, Gavras H. The antiarrhythmic potential of angio- tensin II antagonism: experience with losartan. Am J Hy- pertens 2000;13:512-7.
• Refaat S, El-Ghaffar NA, El-Rahman Negm HA, Yousri T. The role of aldosterone in myocardial dysfunction of Egyp- tian patients with essential hypertension. Arch Med Sci 2008;4:161-6.
• Van den Meiracker AH, Boomsma F. The angiotensin II - sympathetic nervous system connection. J Hypertens 2003;21:1453-4.
• Rocha RM, Silva GV, Perin EC, et al. Effects of carvedilol therapy on QT interval dispersion in congestive heart fail- ure. Tex Heart Inst J 2003;30:176-9.
• Galetta F, Franzoni F, Magagna A, et al. Effect of nebivolol on QT dispersion in hypertensive patients with left ventric- ular hypertrophy. Biomed Pharmacother 2005;59:15-9.
• Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolar- ization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol 2002;90:1107-12.
• Prisant ML. Nebivolol: Pharmacologic profile of an ul- traselective, vasodilatory ß1-blocker. J Clin Pharmacol 2008;48:225-39.
• Sawhney V, Kapoor B, Sharma S, et al. Effects of atenolol and nebivolol on blood pressure and on ECG in patients of stage 1-hypertension–a comparative study. J Clin Diag Research 2008;2:925-31.
• Pagani M, Lucini D. Autonomic dysregulation in essential hypertension: insight from heart rate and arterial pressure variability. Auton Neurosci 2001;90:76-82.